@article{article_1623604, title={PARP1 regulates epigenetic processes through DNMT1 and UHRF1 in oxaliplatin-treated colon cancer cells.}, journal={Ege Tıp Dergisi}, volume={64}, pages={612–620}, year={2025}, DOI={10.19161/etd.1623604}, url={https://izlik.org/JA39TN59FK}, author={Gurbuz Can, Venhar and Kuşat, Tansu}, keywords={PARP1, DNMT1, UHRF1, Epigenetic, Colon Cancer, HT29}, abstract={Aim: Colon cancer is the second most commonly diagnosed cancer among females and the third most frequently diagnosed cancer among males worldwide. Epigenetics is described as alterations in gene expression without changes in nucleotide sequence. Epigenetic mechanisms can modulate the activation or inactivation of cancer-associated genes. The aim of our study was to demonstrate the epigenetic effect of PARP1, DNMT1, and UHRF1 genes in oxaliplatin-treatment colon cancer cell line. Materials and Methods: HT-29 cells were cultured in suitable medium. Then, when the cells were grown up to a certain number, oxaliplatin was applied for 24, 48, and 72 hours at doses of 2.5, 5, 10, 25, 50, 100, and 200 µM to the HT-29 cells, and Cell viability was detected by XTT test. Following the completion of the XTT test, PARP1, DNMT1, and UHRF1 gene expression levels were analyzed by the real-time PCR method. Results: Our results revealed that Oxaliplatin significantly suppressed the expression of UHRF1 and DNMT1 in colon cancer cells, whereas it significantly stimulated the expression of PARP1. Conclusion: In conclusion, the data obtained indicates that the UHRF1, PARP1 and DNMT1 genes may function as modulators of the epigenome and that DNMT1 and UHRF1 interact negatively with PARP1. This study has demonstrated the potential of the UHRF1, PARP1 and DNMT1 genes as targets for colon cancer treatment and as candidate biomarkers.}, number={4}, organization={yok}